Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.53 |
| ▸ | GRM1 | Q13255 | 10/20 | 0.52 |
| ▸ | GRM5 | P41594 | 10/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.51 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | ATR | Q13535 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | CDK7 | P50613 | 1/20 | 0.46 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.46 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22324763 | 1.00 | NAMPT (0.53) | NAMPTGPR119GRM1GRM5CYP11B2 | |
| SCHEMBL15053573 | 0.89 | GPR119 (0.55) | NAMPTGPR119GRM1GRM5CYP11B2 | |
| SCHEMBL23306173 | 0.88 | NAMPT (0.55) | NAMPTGRM1GRM5CYP11B2PDK4 | |
| SCHEMBL29840400 | 0.88 | NAMPT (0.55) | NAMPTGRM1GRM5CYP11B2PDK4 | |
| SCHEMBL29840385 | 0.88 | NAMPT (0.55) | NAMPTGRM1GRM5CYP11B2PDK4 | |
| SCHEMBL30487298 | 0.87 | NAMPT (0.50) | NAMPTGRM1GRM5CYP11B2PDK4 | |
| SCHEMBL29071631 | 0.87 | NAMPT (0.50) | NAMPTGRM1GRM5CYP11B2PDK4 | |
| SCHEMBL29891644 | 0.86 | NAMPT (0.55) | NAMPTGRM1GRM5CYP11B2PDK4 | |
| SCHEMBL15095872 | 0.86 | NAMPT (0.55) | NAMPTGRM1GRM5CYP11B2PDK4 | |
| SCHEMBL31131421 | 0.85 | NAMPT (0.54) | NAMPTGRM1GRM5CYP11B2PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2025-11-25 | — | — | US | disclosed |
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DGKK, DGKG, DGKA | NAMPT 3459/4885GPR119 315/4885GRM1 2125/4885 |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | CYP4A22, ALOX5, ALOX15 | NAMPT 1444/4885GPR119 1008/4885GRM1 2182/4885 |
| US-12479816-B2 | 20-HETE formation inhibitors | CYP4A22, ALOX5, ALOX15 | NAMPT 1444/4885GPR119 1008/4885GRM1 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.